We found that the pre-treatment of leukemia-bearing mice with AZA followed by infusion of anti-CD123 CAR T cells led to improved AML rejection in vivo, which was associated with an improved survival of the mice. This evidence concerns the gene IL3RA and acute myeloid leukemia.